Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis

BACKGROUND: Originator trastuzumab (Herceptin®; H) is an antibody-targeted therapy to treat patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC). We investigated the overall survival (OS) advantage conferred by the addition of H to chemotherapy for HER2+...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Florence R., Coombes, Megan E., Brezden-Masley, Christine, Yurchenko, Mariya, Wylie, Quinlan, Douma, Reuben, Varu, Abhishek, Hutton, Brian, Skidmore, Becky, Cameron, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237027/
https://www.ncbi.nlm.nih.gov/pubmed/30428932
http://dx.doi.org/10.1186/s13643-018-0854-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237027/
https://www.ncbi.nlm.nih.gov/pubmed/30428932
http://dx.doi.org/10.1186/s13643-018-0854-y

Ejemplares similares